Why the study?
Dicloxacillin and flucloxacillin induce CYP-dependent warfarin metabolism, but the clinical impact of these drug-drug interactions on warfarin effectiveness in atrial fibrillation or heart valve replacement was unclear.
Does dicloxacillin or flucloxacillin increase the risk of ischemic stroke or systemic embolism in warfarin users with atrial fibrillation or heart valve replacement?
Does dicloxacillin or flucloxacillin increase the risk of ischemic stroke or systemic embolism in warfarin users with atrial fibrillation or heart valve replacement?
The use of dicloxacillin or flucloxacillin in patients receiving warfarin for atrial fibrillation or heart valve replacement is associated with a significantly increased risk of ischemic stroke and systemic embolism, likely due to CYP450 induction reducing warfarin effectiveness.
Answers are grounded in this paper and cite their sources.
May warrant caution with dicloxacillin/flucloxacillin in warfarin-treated AF; leaves open causal confirmation in RCTs.
The antibiotics dicloxacillin and flucloxacillin induce cytochrome P450-dependent metabolism of warfarin. We explored the influence of these drug-drug interactions on the clinical effectiveness of warfarin therapy due to atrial fibrillation or heart valve replacement. Using the population-based Danish registers, we performed a propensity-score matched cohort study including around 50,000 episodes of dicloxacillin/flucloxacillin matched to phenoxymethylpenicillin and to no antibiotic, respectively. We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) by comparing 21-day (days 7-28) risks of ischemic stroke/systemic embolism (SE) following initiation of each exposure. When compared with phenoxymethylpenicillin, dicloxacillin/flucloxacillin was associated with an HR of ischemic stroke/SE of 2.09 (95% CI 1.51-2.90; strongest for dicloxacillin (HR 2.17; 95% CI 1.56-3.02)). Use of an untreated comparator strengthened the association (HR 2.84; 95% CI 1.97-4.09). Dicloxacillin should be used with caution in patients receiving warfarin. This may also apply to flucloxacillin; however, more data on the risks associated with flucloxacillin exposure during warfarin therapy are needed.
No takes yet. Share an insight, caveat, or question.
Hellfritzsch et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: